Nutrison Protein Intense

A nutritionally complete, high, whole protein, ready-to-use, enteral tube feed.
  • Suitable as a sole source of nutrition.^
  • 50g protein (32%E) per 500ml: to meet international nutrition guidelines for critically ill patients with elevated protein needs.1-4
  • 1.26 kcal/ml: to prevent overfeeding calories.5
  • Whey dominant P4 protein blend: in line with international recommendations on protein quality/amino acid profile6-7 and for gastro-intestinal tolerance benefits.8-13
  • 500ml OpTri bottle: suitable for closed system or open system feeding via ISO compliant flip-top screw cap.

Product Information

A nutritionally complete, high, whole protein, ready-to-use, enteral tube feed.

Link copied!
Indications

For use in the dietary management of critically ill patients requiring high protein enteral feeding including burns, continuous renal replacement therapy (CRRT), obese & multi-trauma patients (as recommended by international guidelines1-4).

Important Notice
  • Not for parenteral use.
  • Not suitable for patients with galactosaemia.
  • Not suitable for patients with cow’s milk protein allergy.
  • Not suitable for infants under 1 year of age or children aged 1-12 years of age due to the high protein content.
  • Use with caution in children from 12 years and upward.
Direction for Use
  • Shake well before use.
  • Use at room temperature.
  • Handle aseptically to ensure product remains sterile.
  • Usage to be determined by a healthcare professional.
Storage
  • Store in a cool, dry place.
  • Once opened, store in the refrigerator.
  • Discard unused contents after 24 hours.
Order Information

Contact Nutricia Customer Care 1800 889 480

Nutrison Protein Intense  Product Code  Units per carton 
500ml OpTri bottle   167812  12 
Ingredients

Full ingredients list and nutritional information available on Factsheet.

Allergen & Cultural Information
  • Contains: cow’s milk protein, soy, fish oil.
  • Does not contain: wheat, egg, nuts*, lupins.
  • Halal certified.
  • No Kosher forbidden ingredients.
  • No gluten containing ingredients. No detectable gluten when tested to a sensitivity level of less than 5 parts per million (<5 ppm i.e. <5mg/kg).
  • Low lactose (lactose <2g/100g).
References
  1. McClave SA, Taylor BE, Martindale RG, et al. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). Journal of Parenteral and Enteral Nutrition. 2016;40:159-211.
  2. Kreymann KG, Berger MM, Deutz NEP, et al. ESPEN Guidelines on Enteral Nutrition: Intensive care. Clin Nutr. 2006;25:210–223.
  3. Dhaliwal R, Cahill N, Lemieux M, et al. The Canadian Critical Care Nutrition Guidelines in 2013: An Update on Current Recommendations and Implementation Strategies. Nutrition in Clinical Practice. 2014;29:29-43.
  4. Sioson MS, Martindale R, Abayadeera A, et al. Nutrition therapy for critically ill patients across the Asia-Pacific and Middle East regions: A consensus statement. Clin Nutr ESPEN. 2018;24:156-164.
  5. van Zanten ARH, Petit L, De Waele J, et al. Very high intact-protein formula successfully provides protein intake according to nutritional recommendations in overweight critically ill patients: a double-blind randomized trial. Critical Care. 2018; 22:156-67.
  6. Hurt RT, McClave SA, Martindale RG, et al. Summary Points and Consensus Recommendations From the International Protein Summit. Nutrition in Clinical Practice. 2017;32:142S–151S.
  7. World Health Organization. Protein and amino acid requirements in human nutrition: report of a joint FAO/ WHO/UNU expert consultation. 2007; WHO technical report series ; no. 935.
  8. Kuyumcu S, Menne D, Curcic J, et al. Noncoagulating enteral formula can empty faster from the stomach: A double-blind, randomized crossover trial using magnetic resonance imaging. Journal of Parenteral and Enteral Nutrition. 2015;39:544-551.
  9. van den Braak CC, Klebach M, Abrahamse E, et al. A novel protein mixture containing vegetable proteins renders enteral nutrition products non-coagulating after in vitro gastric digestion. Clinical Nutrition. 2013;32:765-771.
  10. Klebach M, Hofman Z, Bluemel S, et al. Effect of protein type in enteral nutrition formulas on coagulation in the stomach in vivo: Post hoc analyses of a randomized controlled trial with MRI. Abstract presented at Clinical Nutrition Week, January 16–19; Austin, Tx. Journal of Parenteral and Enteral Nutrition. 2016;40:134(21).
  11. Luttikhold J, van Norren K, Rijna H, et al. Jejunal feeding is followed by a greater rise in plasma cholecystokinin, peptide YY, glucagon-like peptide 1, and glucagon-like peptide 2 concentrations compared with gastric feeding in vivo in humans: a randomized trial. Am J Clin Nutr. 2016;103:435–43.
  12. Abrahamse E, van der Lee S, van den Braak S, et al. Gastric non-coagulation of enteral tube feed yields faster gastric emptying of protein in a dynamic in vitro model. Abstract presented at 34th ESPEN Congress. Sept 8-11; Barcelona, Spain. Clinical Nutrition Supplements. 2012;7:PP239(119).
  13. Liu J, Klebach M, Abrahamse E, et al. Specific protein mixture reduces coagulation: An in vitro stomach model study mimicking a gastric condition in critically ill patients. Poster presented at 38th ESPEN Congress. 17- 20 September; Copenhagen, Denmark. Clinical Nutrition. 2016;35:MON-P182 (S220). 
Additional Information

^ In accordance with Australia New Zealand Food Standards Code – Standard 2.9.5

 

* Peanut (Arachis hypogaea), Almond (Amygdalus communis L .), Hazelnut (Corylus avellana), Walnut (Juglans regia), Cashew (Anacardium occidentale), Pecan nut (Carya illinoiesis (Wangenh.) K. Koch), Brazil nut (Bertholletia excelsa), Pistachio nut (Pistacia vera), Macadamia nut and Queensland nut (Macadamia ternifolia), and products thereof.